Difference between revisions of "Talimogene Laherparepvec: A groundbreaking viral therapy for late stage melanoma"

From MicrobeWiki, the student-edited microbiology resource
Jump to: navigation, search
Line 1: Line 1:
 
<!-- Do not edit this line-->{{Curated}}
 
<!-- Do not edit this line-->{{Curated}}
 
==Introduction==
 
==Introduction==
[[File:http://darwin.bio.uci.edu/~faculty/wagner/hsvimg01.jpg]]
+
 
 +
[[Image:http://darwin.bio.uci.edu/~faculty/wagner/hsvimg01.jpg|thumb|300px|right|<b> Figure 1:</b> Scatter plot representing the effect of <i> Bifidobacterium longum </i> subsp. <i> infantis </i> on intestinal epithelial cell viability. The study was done by O'Hara et al in 2006 [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2567.2006.02358.x/full].]]  
 +
 
 
<br>By Alex Fazioli<br>
 
<br>By Alex Fazioli<br>
<br>At right is a sample image insertionIt works for any image uploaded anywhere to MicrobeWiki.<br><br>The insertion code consists of:
+
<br>Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [1]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [1]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [2]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [3].
 +
 
 
<br><b>Double brackets:</b> [[
 
<br><b>Double brackets:</b> [[
 
<br><b>Filename:</b> PHIL_1181_lores.jpg
 
<br><b>Filename:</b> PHIL_1181_lores.jpg

Revision as of 20:29, 2 April 2018

This is a curated page. Report corrections to Microbewiki.

Introduction

File:Http://darwin.bio.uci.edu/~faculty/wagner/hsvimg01.jpg
Figure 1: Scatter plot representing the effect of Bifidobacterium longum subsp. infantis on intestinal epithelial cell viability. The study was done by O'Hara et al in 2006 [1].


By Alex Fazioli

Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [1]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [1]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [2]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [3].


Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Electron micrograph of the Ebola Zaire virus. This was the first photo ever taken of the virus, on 10/13/1976. By Dr. F.A. Murphy, now at U.C. Davis, then at the CDC.
Closed double brackets: ]]

Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+


Introduce the topic of your paper. What is your research question? What experiments have addressed your question? Applications for medicine and/or environment?
Sample citations: [1] [2]

A citation code consists of a hyperlinked reference within "ref" begin and end codes.

Classification

Baltimore classification: dsDNA
Family: Herpesviridae
Virion: Enveloped
Capsid symmetry: Icosahedral
Replication site: Nucleus and cytoplasm

Section 2

Include some current research, with at least one figure showing data.

Section 3

Include some current research, with at least one figure showing data.

Section 4

Conclusion

References



Authored for BIOL 238 Microbiology, taught by Joan Slonczewski, 2018, Kenyon College.